Boom in the development of non-peptidic β-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease

Medicinal Research Reviews

Volumn 29, Issue 2, 2009, Pages 295-338

  Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

secretase; Alzheimer's disease; BACE1; Non peptidic inhibitors

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ACC 001; ALZHEIMER DISEASE VACCINE; AP 2238; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; E 2012; GAMMA SECRETASE INHIBITOR; GT 1017; GUANIDINE DERIVATIVE; HETEROCYCLIC COMPOUND; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONICOTINAMIDE; ISPRONICLINE; KMI 249; KMI 429; KMI 570; KMI 684; LACTAM DERIVATIVE; LADOSTIGIL; LY 2062430; MEM 3454; MEVINOLIN; MK 0752; MORPHOLINE DERIVATIVE; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; OM 00 3; OM 99 2; PF 4360365; SIMVASTATIN; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; PROTEINASE INHIBITOR; SECRETASE;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CYCLIZATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG ANTAGONISM; DRUG INDUSTRY; ENZYMOLOGY; METABOLISM; RESEARCH;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; DRUG INDUSTRY; PROTEASE INHIBITORS; RESEARCH; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 62249167406     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20132     Document Type: Review

References (206)

1. Melnikova I. Therapies for Alzheimer's disease. Nat Rev Drug Disc 2007;6:341-342. (Pubitemid 46696548)
2. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neur 2004;5:677-685. (Pubitemid 39150139)
3. WHO: Alzheimer's disease. http://www.who.int/en/.
4. Verdon C-M, Fossati P, Verny M, Dieudonne B, Teillet L, Nadel J. Social cognition: An early impairment in dementia of the Alzheimer type. Alzh Dis Ass Dis 2007;21:25-30.
5. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-417. (Pubitemid 12048290)
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-357.
7. Nguyen J-T, Yamani A, Kiso Y. Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease: Progress and problems. Curr Pharm Des 2006;12:4295-4312.
8. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003;278:11612-11622.
9. Espeseth AS, Xu M, Huang Q, Coburn CA, Jones KLG, Ferrer M, Zuck PD, Strulovici B, Price EA, Wu G, Wolfe AL, Lineberger JE, Sardana M, Tugusheva K, Pietrak BL, Crouthamel M-C, Lai M-T, Dodson EC, Bazzo R, Shi X-P, Simon AJ, Li Y, Hazuda DJ. Compounds that bind APP and inhibit a processing in vitro suggest a novel approach to Alzheimer's disease therapeutics. J Biol Chem 2005;280:17792-17797. (Pubitemid 41389018)
10. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693-4697.
11. Rubio A, Avila J, Pérez M. Effect of acetylcholine on tau phosphorylation in human neuroblastoma cells. J Mol Neurosci 2006;30:185-188. (Pubitemid 46035364)
12. Hardy J. The Alzheimer family of diseases: Many etiologies, one pathogenesis? Proc Natl Acad Sci USA 1997;94:2095-2097.
13. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EB, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer's-related amyloid b oligomers. J Neurosci 2004;24:10191-10200. (Pubitemid 39492046)
14. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Ab oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007;27:796-807. (Pubitemid 46174498)
15. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge Y-W, Lahiri DK, Zawia NH. The fetal basis of amyloidogenesis: Exposure to lead and latent overexpression of amyloid precursor protein and amyloid in the aging brain. J Neurosci 2005;25:823-829.
16. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717.
17. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007;27:2866-2875. (Pubitemid 46438992)
18. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-498.
19. Montalto MC, Farrar G, Hehir CT. Fibrillar and oligomeric β-amyloid as distinct local biomarkers for Alzheimer's disease. Ann New York Acad Sci 2007;1097:239-258. (Pubitemid 47084898)
20. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997;272:348-361. (Pubitemid 27410049)
21. Castro A, Martinez A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 2006;12:4377-4387.
22. Du D-M, Carlier PR. Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease. Curr Pharm Design 2004;10:3141-3156. (Pubitemid 39242909)
23. Tezer N. Ab initio molecular structure study of alkyl substitute analogues of Alzheimer drug phenserine: Structure-activity relationships for acetyl- and butyrylcholinesterase inhibitory action. Theochem 2005;714:133-136.
24. Del Monte-Millán M, Gracía-Palomero E, Valenzuela R, Usán P, de Austria C, Muñoz-Rulz P, Rubio L, Dorronsoro I, Martínez A, Medina M. Dual binding site acetylcholinesterase inhibitors: Potential new disease-modifying agents for AD. J Mol Neurosci 2006;30:85-88.
25. Bai D. Development of huperzine A and B for treatment of Alzheimer's disease. Pure Appl Chem 2007;79:469-479.
26. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996;16:881-891.
27. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid-peptide fibril formation. Biochemistry 2001;40:10447-10457. (Pubitemid 32816655)
28. Giacobini E. Cholinesterase inhibitors stabilize Alzheimer's disease. Neurochem Res 2000;25:1185-1190.
29. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of beta-amyloid precursor protein in cell lines. J Neurosci Res 1994;37:777-787. (Pubitemid 24125794)
30. Rees TM, Brimijoin S. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs Today 2003;39:75-83. (Pubitemid 36378463)
31. Gozes I. Tau as a drug target in Alzheimer's disease. J Mol Neurosci 2002;19:337-338. (Pubitemid 36051526)
32. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neur Aging 2002;23:1031-1038. (Pubitemid 35447784)
33. Klafki H-W, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006;129:2840-2855. (Pubitemid 44684507)
34. Permanne BM, Saborio GP, Soto C. In vivo disrupting of amyloid deposition after injection of β-sheet breaker peptide into cerebral ventricle. Neur Aging 2000;21(S1):S87.
35. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MHL, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SSN, Mount HTJ, Fraser PE, Westaway D, StGeorge-Hyslop P. Cyclohexanehexol inhibitors of A aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nature Med 2006;12:801-808. (Pubitemid 44050070)
36. de Mattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855. (Pubitemid 32678116)
37. (a)Revill P, Serradell N, Bolos J. Tramiprosate: Antiamyloidogenic agent for treatment of Alzheimer's disease and hemorrhagic stroke. Drugs Fut 2006;31:498-501;37. (Pubitemid 44406097)
38. (b)Wright TM. Tramiprosate. Drugs Today 2006;42:291-298.
39. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neur Aging 1995;16:271-278.
40. Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman PJ, Growdon JH, Selkoe DJ. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 1993;268:22959-22962. (Pubitemid 23327996)
41. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-307.
42. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojiro E. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer's disease mouse model. J Clin Invest 2004;113:1456-1464. (Pubitemid 39071701)
43. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, Von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-5861. (Pubitemid 32435732)
44. Kojiro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM10. Proc Natl Acad Sci USA 2001;98:5815-5820. (Pubitemid 32435725)
45. Larner AJ. Secretases as therapeutic targets in Alzheimer's disease: Patents 2000-2004. Expert Opin Ther Pat 2004;14:1403-1420.
46. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998;391:387-390. (Pubitemid 28093512)
47. Petit A, Bihel F, Alves da Costa C, Pourquie O, Checler F, Kraus JL. New protease inhibitors prevent gamma-secretase-mediated production of Aβ40/42 without affecting Notch cleavage. Nat Cell Biol 2001;3:507-511.
48. Campbell WA, Reed ML, Strahle J,Wolfe MS, Xia W. Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase. J Neurochem 2003;85:1563-1574. (Pubitemid 36702568)
49. Wolfe MS. Therapeutic strategies for Alzheimer's disease. Nat Rev Drug Disc 2002;1:859-865.
50. Teall M, Oakley P, Harrison T, Shaw D, Kay E, Elliott J, Gerhard U, Castro JL, Shearman M, Ball RG, Tsou NN. Aryl sulfones: A new class of γ-secretase inhibitors. Bioorg Med Chem Lett 2005;15:2685-2688.
51. Churcher I, Beher D. γ-Secretase as a therapeutic target for the treatment of Alzheimer's disease. Curr Pharm Des 2005;11:3363-3382. (Pubitemid 41300765)
52. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Donald L, Wong PC. BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nature Neurosci 2001;4:233-234. (Pubitemid 32194867)
53. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naeslund J, Lannfelt L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation. Nature Neurosci 2001;4:887-893.
54. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402:537-540.
55. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science 2000;290:150-153.
56. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, Hong L, Loy JA, Nguyen C, Koelsh G, Ermolieff J, Tang J. Structure-based design: Potent inhibitors of human brain memapsin 2 (β-secretase). J Med Chem 2001;44:2865-2868.
57. Ghosh AK, Tang J, Bilcer G, Chang W, Hong L, Koelsch G, Loy J, Turner RT III. β-Secretase inhibitors and methods of use. PCT Int Appl 2003; WO03039454.
58. Ghosh AK, Devasamudram T, Hong L, Dezuter C, Xu X, Weerasena V, Koelsch G, Bilcer G, Tang J. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 β-secretase. Bioorg Med Chem Lett 2005;15:15-20. (Pubitemid 39575774)
59. Shuto D, Kasai S, Kimura T, Liu P, Hidaka K, Hamada T, Shibakawa S, Hayashi Y, Hattori C, Szabo B, Ishiura S, Kiso Y. KMI-008, a novel beta-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: Design and synthesis of substrate-based octapeptides. Bioorg Med Chem Lett 2003;13:4273-4276.
60. Kimura T, Shuto D, Kasai S, Liu P, Hidaka K, Hamada T, Hayashi Y, Hattori C, Asai M, Kitazume S, Saido TC, Ishiura S, Kiso Y. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorg Med Chem Lett 2004;14:1527-1531. (Pubitemid 38299443)
61. Manzenrieder F, Frank AO, Huber T, Dorner-Ciossek C, Kessler H. Synthesis and biological evaluation of phosphino dipeptide isostere inhibitor of human β-secretase (BACE1). Bioorg Med Chem 2007;15:4136-4143. (Pubitemid 46678841)
62. Kimura T, Shuto D, Hamada Y, Igawa N, Kasai S, Liu P, Hidaka K, Hamada T, Hayashi Y, Kiso Y. Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 2005;15:211-215. (Pubitemid 39575813)
63. Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabò B, Hashimoto Y, Maruyama K, Tanuma S, Kiso Y, Ishiura S. The novel β-secretase inhibitor KMI-429 reduces amyloid b peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006;96:533-540.
64. Kimura T, Hamada Y, Stochaj M, Ikari H, Nagamine A, Abdel-Rahman H, Igawa N, Hidaka K, Nguyen J-T, Saito K, Hayashi Y, Kiso Y. Design and synthesis of β-secretase (BACE1) inhibitors with P1′ carboxylic acid bioisosteres. Bioorg Med Chem Lett 2006;16:2380-2386.
65. Boyd JG, Singleton DH. Novel inhibitor of β-amyloid cleavage enzyme. US Pat Appl 2002;US2002115616.
66. Chen S-H, Lamar J, Guo D, Kohn T, Yang H-C, McGee J, Timm D, Erickson J, Yip Y, May P, McCarthy J. P3 cap modified Phe*-Ala series BACE inhibitors. Bioorg Med Chem Lett 2004;14:245-250. (Pubitemid 38010226)
67. Tung JS, Davis DL, Anderson JP,Walker DE, Mamo S, Jewett N, Hom RK, Sinha S, Thorsett ED, John V. Design of substrate-based inhibitors of human β-secretase. J Med Chem 2002;45:259-262. (Pubitemid 34073445)
68. Bradly F, Singh S, Crouthamel MC, Holloway MK, Coburn CA, Grasky VM, Bogusky M, Pennington MW, Vacca JP, Hazuda D, Lai M-T. Rational design and synthesis of selective BACE1 inhibitors. Bioorg Med Chem Lett 2004;14:601-614. (Pubitemid 38120278)
69. Hills DH, Vacca JP. Progress toward a practical BACE1 inhibitor. Curr Opin Drug Disc Dev 2007;10:383-391. (Pubitemid 47093121)
70. Guo T, Hobbs DW. Development of BACE1 inhibitors for Alzheimer's disease. Curr Med Chem 2006;13:1811-1829. (Pubitemid 43871758)
71. Ziora Z, Kimura T, Kiso Y. Small-sized BACE1 inhibitors. Drug Fut 2006;31:53-63.
72. Limongelli V, Marinelli L, Cosconati S, Braun HA, Schmidt B, Novellino E. Ensemble-docking approach on BACE1: Pharmacophore perception and guidelines for drug design. Chem Med Chem 2007;2:667-678.
73. Eder J, Hommel U, Cumin F, Martoglio B, Gerhartz B. Aspartic proteases in drug discovery. Curr Pharm Des 2007;11:271-285. (Pubitemid 46085279)
74. Gao J, Winslow SL, Vander Velde D, Aube J, Borchardt RT. Transport characteristics of peptides and peptidomimetics: II. Hydroxyethylamine bioisostere-containing peptidomimetics as substrates for the oligopeptide transporter and P-glycoprotein in the intestinal mucosa. J Pept Res 2001;57:361-371.
75. Miyamoto M, Matsui J, Fukumoto H, Tarui N. (Takeda Chem Ind) Preparation of 2-[2-amino- or 2-(N-heterocyclyl)ethyl]-6-(4-biphenylylmethoxy)tetralin derivatives as β-secretase inhibitors. PCT Int Appl 2001; WO2001087293.
76. Miyamoto M, Matsui J, Fukumoto H, Tarui N. (Takeda Chem Ind) Beta-secretase inhibitors. Jpn Pat Appl 2002; JP2002037731.
77. Miyamoto M, Matsui J, Fukumoto H,Tarui N. (Takeda Chem Ind)-Secretase inhibitors. Eur Pat Appl 2003;EP1283039.
78. Uchikawa O, Aso K, Koike T, Tarui N, Hirai K. (Takeda Chem Ind) Preparation of benzamide derivatives as β-secretase inhibitors. PCT Int Appl 2004; WO 2004014843.
79. Watanabe H, Kurasawa O, Tarui N, Yorimoto T, Hirai K. (Takeda Chem Ind) Preparation of indoles as inhibitors against aspartate protease, β-secretase, and amyloid β protein for treatment of nerve disorders and myopathy. Jpn Pat Appl 2004; JP2004149429.
80. Qiao L, Etchenberrigaray R. (Neurologic Inc.) Preparation of phosphinylmethyl and phosphorylmethyl succinic and glutaric acid analogs as β-secretase inhibitors useful in the treatment of Alzheimer's disease. PCT Int Appl 2002; WO2002096897.
81. Etchenberrigaray R, Qiao L. (Neurologic Inc.) Phosphinylmethyl and phosphorylmethyl succinic and glutaric acid analogs as β-secretase inhibitors. PCT Int Appl 2003; US2003078240.
82. Bhisetti GR, Saunders JO, Murcko MA, Lepre CA, Britt SD, Come JH, Deninger DD, Wang T. (Vertex Pharm. Inc.) Preparation of β-carbolines and other inhibitors of BACE1 aspartic proteinase useful against Alzheimer's and other BACE-mediated diseases. PCT Int Appl 2002; WO2002088101.
83. John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL. Human β-secretase (BACE) and BACE inhibitors. J Med Chem 2003;46:4625-4630. (Pubitemid 37271610)
84. Elan Pharm, Inc. Statine-derived tetrapeptide inhibitors of β-secretase. Exp Opin Ther Pat 2001;11:1047-1050.
85. John V, Tung J, Fang L, Mamo SS. (Elan Pharm. Inc.) Preparation of statine-derived tetrapeptides as inhibitors of β-secretase. PCT Int Appl 2000; WO2000077030.
86. Hom RK, Gailunas AF, Mamo S, Fang LY, Tung JS,Walker DE, Davis D, Thorsett ED, Jewett NE, Moon JB, John V. Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human bsecretase. J Med Chem 2004;47:158-164. (Pubitemid 38040499)
87. Tung JS, Davis DL, Anderson JP,Walker DE, Mamo S, Jewett N, Hom RK, Sinha S, Thorsett ED, John V. Design of substrate-based inhibitors of human β-secretase. J Med Chem 2002;45:259-262. (Pubitemid 34073445)
88. Maillard MC, Hom RK, Benson TE, Moon JB, Mamo S, Bienkowski M, Tomasselli AG, Woods DD, Prince DB, Paddock DJ, Emmons TL, Tucker JA, Dappen MS, Brogley L, Thorsett ED, Jewett N, Sinha S, John V. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human β-secretase. J Med Chem 2007;50:776-781. (Pubitemid 46332990)
89. Hom R, Mamo S, Tung J, Gailunas A, John V, Fang LY. (Elan Pharm. Inc.) Preparation of hydroxyethylenes with peptide subunits for pharmaceutical use in the treatment of Alzheimer's disease. PCT Int Appl 2001; WO2001070672.
90. Fang LY, Hom R, John V, Maillaird M. (Elan Pharm. Inc.) Preparation of substituted amines for the treatment of Alzheimer's disease. PCT Int Appl 2002; WO2002002505.
91. Maillard M, Hom C, Gailunas A, Jagodzinska B, Fang LY, John V, Freskos JN, Pulley SR, Beck JP, Tenbrink RE. (Elan Pharm. Inc.) Preparation of substituted amines to treat Alzheimer's disease. PCT Int Appl 2002; WO2002002512.
92. Beck JP, Gailunas A,Hom R, Jagodzinska B, John V, Maillaird M. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of disubstituted amines for treating Alzheimer's disease. Eur Pat Appl 2001; EP1586556. PCT Int Appl 2002; WO2002002518.
93. John V, Hom R, Tucker J. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of β-hydroxyamine derivatives for the treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003002122.
94. John V. (Elan Pharm. Inc.) Preparation of peptide isosteres containing a heterocycle useful in the treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003047576.
95. John V, Maillard M, Tucker J, Aquino J, Jagodzinska B, Brogley L, Tung J, Bowers S, Dressen D, Probst G, Shah N. (Elan Pharm. Inc.) Preparation of hydroxyethylamines as aspartyl protease inhibitors for treatment of amyloidosis. PCT Int Appl 2005; WO2005087751. and 2005; WO2005087752.
96. John V, Hom R, Tucker J. Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors. US Pat Appl 2006; US20060014737.
97. Nieman JA, Fang L, Jagodzinska B. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Methods of treating or preventing Alzheimer's disease using 4-aryl-3-aralkoxypipiperidines and azabicyclooctanes. PCT Int Appl 2002; WO2002076440.
98. Schostarez H, Chrusciel RA, Cenko RS. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Acylaminopropylhydrazines as β-secretase inhibitors. PCT Int Appl 2002; WO2002094768.
99. Pulley SR, Beck JP, Tenbrink RE, Jacobs JS. (Elan Pharm. Inc. Pharmacia & Upjohn Comp.) Preparation of macrocycles useful in the treatment of Alzheimer's disease. PCT Int Appl 2002; WO2002100399.
100. Pulley SR, Beck JP, Tenbrink RE. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Macrocycles useful in the treatment of Alzheimer's disease. PCT Int Appl 2002; WO2002100856.
101. Schostarez HJ, Chrusciel RA. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of aminediols as β-secretase inhibitors for the treatment of Alzheimer's and other diseases characterized by deposition of Aβ peptide. PCT Int Appl 2002; WO2002100818.
102. Schostarez HJ, Hanson GJ. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Aminodiols useful in the treatment of Alzheimer's disease and similar diseases. PCT Int Appl 2003; WO2003043618.
103. Romero AG, Schostarez H, Roels CM. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of amine 1,2- and 1,3-diol alditols and their use for treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003043975.
104. Beck JP. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation and use of aza-bicyclononanes for the treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003000261.
105. Schostarez HJ, Chrusciel RA. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of diamine diols as β-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003006013.
106. Schostarez HJ, Chrusciel RA. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of diamine diols as β-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003006453.
107. Gailunas A, Hom R, John V, Mailard M, Chrusciel RA, Fisher J, Jacobs J, Freskos JN, Brown DL, Fobian YM. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of N-(3-amino-2-hydroxypropyl) substituted alkanamides as inhibitors of the beta secretase enzyme for treating Alzheimer's disease. PCT Int Appl 2003; WO2003006423.
108. Aquino J, John V, Tucker JA, Hom R, Pulley S, Tenbrink R. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of 2-hydroxy-3- aminoalkylbenzamides as β-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int Appl 2004; WO2004094384.
109. Gailunas AT, Tucker JA, John V. Preparation of phenethylamines for the treatment of Alzheimer's disease. (Elan Pharm. Inc.). PCT Int Appl 2003; WO2003027068.
110. Fisher JF, Jacobs JS, Scherer BA. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of arylhydroxypropylamines used for treatment of Alzheimer's disease and to reduce amyloid beta peptide formation. PCT Int Appl 2003; WO2003029169.
111. Roy H. (Elan Pharm. Inc.) Preparation of allylamides useful in the treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003030886.
112. Beck JP. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of hydroxy substituted indanylamides for the treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003037325.
113. John V, Maillard M, Jagodzinska B, Beck JP, Gailunas A, Fang L, Sealy J, Tenbrink R, Freskos J, Mickelson J, Samala L, Hom R. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of N0, N′-susbstituted-1,3- diamino-2-hydroxypropanes for treating Alzheimer's disease. PCT Int Appl 2003; WO2003040096.
114. Jagodzinska B, Maillard M, Beck JP, Tenbrink R, Getman D. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of substituted amine as prodrugs useful in treating Alzheimer's disease. PCT Int Appl 2003; WO2003072535.
115. Fobian YM, Freskos JN, Jagodzinska B. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) A preparation of 1,3-diamino-2-hydroxypropane derivatives as beta-secretase enzyme inhibitors. PCT Int Appl 2004; WO2004022523.
116. Maillard M, Baldwin ET, Beck JT, Hughesm R, John V, Pulley SR, Tenbrink R. (Elan Pharm. Inc., Pfizer, Inc., Pharmacia & Upjohn Comp.) Preparation of ring-containing N-acetyl 2-hydroxy-1,3-diamonoalkanes as β-secretase inhibitors for treating Alzheimer's disease and other diseases characterized by deposition of Aβ-peptide. PCT Int Appl 2004; WO2004024081.
117. Aquino J, John V, Tucker JA, Hom R, Pulley S, Tenbrink R. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of phenacyl-substituted 2-hydroxy-3-diaminoalkanes as inhibitors of β-secretase. PCT Int Appl 2004; WO2004094413.
118. John V, Moon JB, Pulley SR, Rich DH, Brown D. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of substituted piperidines and piperazines useful as β-secretase inhibitors against Alzheimer's disease. PCT Int Appl 2003; WO2003043987.
119. Tenbrink R, Maillard M, Warpehoski M. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of substituted hydroxyethylamines as β-secretase inhibitors. PCT Int Appl 2003; WO2003050073.
120. Jagodzinska B, Warpehoski MA. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of substituted amino carboxamides for the treatment of Alzheimer's disease. PCT Int Appl 2003; WO2003057721.
121. Maillard M, Varghese J. (Elan Pharm. Inc) Methods of treating Alzheimer's disease using aromatically substituted ω-aminoalkanoic acid amides and alkanoic acid diamides. PCT Int Appl 2003; WO2003103652.
122. John V, Maillard M. (Elan Pharm. Inc) Methods of treating Alzheimer's disease and methods of preparing δ-amino-γ-hydroxy-ω- arylalkanoic acid amides. PCT Int Appl 2003; WO2003103653.
123. Hom R, Varghese J. (Elan Pharm. Inc.) Preparation of hydroxyaminopropyl benzamides for the treatment of Alzheimer's disease. PCT Int Appl 2004; WO2004029019.
124. Tucker JA. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of hydroxypropyl amide peptide analogs for the treatment of Alzheimer's disease. PCT Int Appl 2005; WO2005042472.
125. Pulley SR, Tucker JA. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of peptide-related substituted ureas and carbamates for the treatment of Alzheimer's disease. PCT Int Appl 2004; WO2004050609.
126. John V, Maillard M, Tucker J, Aquino J, Hom R, Tung J, Dressen D, Shah N, Neitz RJ. (Elan Pharm. Inc.) Preparation of substituted ureas and carbamates, phenacyl-2-hydroxy-3-diaminoalkane and benzamide-2- hydroxy-3-diaminoalkane aspartyl protease and β-secretase inhibitors for treating conditions associated with amyloidosis such Alzheimer's disease. PCT Int Appl 2005; WO2005087215.
127. John V, Hom R, Saely J, Aquino J, Probst G, Tung J, Fang L. (Elan Pharm. Inc.) Preparation of N-(3-amino- 2-hydroxypropyl)acetamides as aspartyl protease and beta-secretase inhibitors for treating conditions associated with amyloidosis such Alzheimer's disease. PCT Int Appl 2005; WO2005070407.
128. John V, Maillard M, Fang L, Tucker J, Brogley L, Aquino J, Bowers S, Probst G, Tung J. (Elan Pharm. Inc.) Preparation of bicyclic compounds as aspartyl protease and beta-secretase inhibitors for treating conditions associated with amyloidosis such Alzheimer's disease. PCT Int Appl 2005; WO2005087714.
129. Hom R, Tucker J, John V, Shah N. (Elan Pharm. Inc., Pharmacia & Upjohn Comp.) Preparation of 2-amino- and 2-thio-substituted 1,3-diaminopropanes as β-secretase inhibitors for treating Alzheimer's disease and other diseases characterized by deposition of Aβ-peptide. PCT Int Appl 2005; WO2005095326.
130. John V, Maillard M, Jagodzinska B, Aquino J, Probst G, Tung JS. (Elan Pharm. Inc.) Preparation of oxime, hydrazone and other derivative substituted hydroxyethylamine selective β-secretase inhibitors for treating amyloidosis. PCT Int Appl 2006; WO2006010095.
131. Sealy J, Hom R, John V, Probst G, Tung JS. (Elan Pharm. Inc.) Preparation of oxime-containing N-(3-amino-1-arylmethyl-2-hydroxypropyl) carboxamides and related selective β-secretase inhibitors for treating amyloidosis. PCT Int Appl 2006; WO2006010094.
132. Hom R, Fang L, John V. (Elan Pharm. Inc.) Preparation of ethanolcyclicamines selective β-secretase inhibitors for treatment of amyloidosis. PCT Int Appl 2006; WO2006026533 and 2006; WO2006026532.
133. Hom R, Toth G, Probst G, Bowers S, Truong A, Tung JS. (Elan Pharm. Inc.) Preparation of aryl cyclopropyl(heterocyclyl)aminohydroxybutylamides as aspartyl protease inhibitors for treatment of amyloidosis. PCT Int Appl 2007; WO2007047306 and 2007; WO2007047305.
134. Coburn CA, Stachel SJ, Li Y-M, Rush DM, Steele TG, Chen-Dodson E, Holloway MK, Xu M, Huang Q, Lai M-T, Di Muzio J, Crouthamel M-C, Shi X-P, Sardana V, Chen Z, Munshi S, Kuo L, Makara GM, Annis DA, Tadikinda PK, Nash HM, Vacca JP, Wang T. Identification of a small molecule nonpeptide active site β-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J Med Chem 2004;47:6117-6119. (Pubitemid 39587236)
135. Coburn CA, Steele TG, Vacca JP, Annis DA Jr, Makara GM, Nash HM, Tadikonda PK, Praveen K, Wang T. (Merck & Co.) Preparation of aminopently-aminooxoethylphenylcarboxamides as β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2005; WO2005113484.
136. Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai M-T, Crouthamel M-C, Xu M, Tugusheva K, Lineberger JE, Pietrak BL, Espeseth AS, Shi X-P, Chen-Dodson E, Holloway M-K, Munshi S, Simon AJ, Kuo L, Vacca JP. Structure-based design of potent and selective cell-permeable inhibitors of human β-secretase (BACE1). J Med Chem 2004;47:6447-6450. (Pubitemid 39657304)
137. Coburn CA, Stachel SJ, Vacca JP. Preparation of phenylcarboxamide derivatives as β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2004; WO2004043916.
138. Stachel SJ, Coburn CA, Steele TG, Crouthamel M-C, Pietrak BL, Lai M-T, Holloway MK, Munshi SK, Graham SL, Vacca JP. Conformationally biased P3 amide replacements of β-secretase inhibitors. Bioorg Med Chem Lett 2006;16:641-644. (Pubitemid 43014850)
139. 2NH] reduced amide isosteres. Bioorg Med Chem Lett 2006;16:3635-3638.
140. Coburn CA, Stachel SJ, Vacca JP. (Merck & Co.) N-alkyl phenylacetamides beta-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2005; WO2005004802.
141. Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Pietrak BL, Huang Q, Lineberger J, Espeseth AS, Jin L, Ellis J, Holloway MK, Munshi S, Allison T, Hazuda D, Simon AJ, Graham SL, Vacca JP. Macrocyclic inhibitors of β-secretase: Functional activity in an animal model. J Med Chem 2006;49:6147-6150.
142. Coburn CA, Stachel SJ, Vacca JP. (Merck & Co.) Preparation of macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease. PCT Int Appl 2005; WO2005018545.
143. Holloway MK, McGaughey GB, Coburn CA, Stachel SJ, Jones KG, Stanton EL, Gregro AR, Lai M-T, Crouthamel M-C, Pietrak BL, Munshi SK. Evaluating scoring functions for docking and designing β-secretase inhibitors. Bioorg Med Chem
144. Stauffer SR, Stanton MG, Gregro AG, Steinbeiser MA, Shaffer JR, Nantermet PG, Barrow JC, Rittle KE, Collusi D, Espeseth AS, Lai M-T, Pietrak BL, Holloway MK, McGaughey GB, Munshi SK, Hochman JH, Simon AJ, Selnick HG, Graham SL, Vacca JP. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation. Bioorg Med Chem Lett 2007;17:1788-1792. (Pubitemid 46274326)
145. Stanton MG, Stauffer SR, Gregro AR, Steinbeiser M, Nantermet P, Sankaranarayanan S, Price EA, Wu G, Crouthamel M-C, Ellis J, Lai M-T, Espeseth AS, Shi X-P, Jin L, Colussi D, Pietrak B, Huang Q, Xu M, Simon AJ, Graham SL, Vacca JP, Selnick H. Discovery of isonicotinamide derived β-secretase inhibitors: in vivo reduction of β-amyloid. J Med Chem 2007;50:3431-3433. (Pubitemid 47195452)
146. Barrow JC, McGaughey GB, Nantermet PG, Rajapakse HA, Selnick HG, Stauffer SR, Coburn CA. (Merck & Co.) Preparation of 1,3,5-substituted phenyl derivatives containing five-membered heterocycles useful as β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2005; WO2005103020.
147. Barrow JC, McGaughey GB, Nantermet PG, Rajapakse HA, Selnick HG, Stauffer SR, Shaun R, Vacca JP, Stachel SJ, Coburn CA, Stanton MG. (Merck & Co.) Preparation of amino oxadiazolyl pyridinil sulfonamides as β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2005; WO2005103043.
148. Coburn CA, Espeseth AS, Stachel SJ, Olsen DB, Hazuda D, Holloway MK. (Merck & Co.) Preparation of 2-aminothiazole compounds as aspartyl protease inhibitors. PCT Int Appl 2005; WO200597767.
149. Barrow JC, Coburns CA, Nantermet PG, Selnick HG, Stachel SJ, Shawn J, Stanton MG, Stauffer SR, Zhuang L, Davis JR. (Merck & Co.) Preparation of phenylamides and pyridylamides as β-secretase inhibitors. PCT Int Appl 2005; WO2005065195.
150. Coburn CA. (Merck&Co.) Pyrrolidin-3-yl compounds, synthesis, pharmaceutical compositions and their use as β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2006; WO2006002004.
151. Barrow JC, Coburn CA, Egbertson MS, McGaughey GB, McWheter MA, Neilson LA, Selnick HG, Stauffer SR, Yang Z-Q, Yang W, Lu W, Fahr B, Rittle KE. (Merck & Co., and Sunesis Pharm.) Preparation of spiropiperidine compounds as β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2006; WO2006044497.
152. Coburn CA, Holloway MK, Stachel SJ. (Merck & Co.) Preparation of aminopyridines as β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2006; WO2006060109.
153. Coburn CA, Nantermet PG, Rajapakse HA, Selniuck HG, Stauffer SR. (Merck & Co.) Amino-methyl β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2006; WO2006078576.
154. Coburn CA, Egberston MS, Graham SL, Mcgaughey GB, Stauffer SR, Yang W, Lu W, Fahr B. (Merck & Co., and Sunesis Pharm.) Spiropiperidine as β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2007; WO2007011810.
155. Coburn CA, Egberston MS, Graham SL, Mcgaughey GB, Stauffer SR, Rajapakse HA, Nantermet PG, Stachel SR, Yang W, Lu W, Fahr B. (Merck & Co. and Sunesis Pharm.) Spiropiperidine as β-secretase inhibitors for treatment of Alzheimer's disease β-secretase inhibitors for treatment of Alzheimer's disease. PCT Int Appl 2007; WO2007011833.
156. Xue Q, Albrecht BK, Andersen DL, Bartberger M, Brown J, Brown R, Chaffee SC, Cheng Y, Croghanm M, Graceffa R, Harried S, Hitchcock S, Hungate R, Judd T, Kaller M, Kreiman C, La D, Lopez P, Masse CE, Monenschein H, Nguyen T, Nixwy T, Patel VF, Pennington L, Weiss M, Yang B, Zhong W. (Amgen Inc.) Preparation of 2-hydroxy-1,3-diaminoalkanes including spiro substituted chroman derivatives as β-secretase modulators and their use for treatment Alzheimer's disease and related condition. PCT Int Appl 2007; WO2007061930.
157. Albrecht BK, Andersen DL, Bartberger M, Brown J, Brown R, Chaffee SC, Cheng Y, Croghan M, Graceffa R, Harried S, Hitchcock S, Hungate R, Judd T, Kaller M, Kreiman C, La D, Lopez P, Masse CE, Monenschein H, Nguyen T, Nixey T, Patel VF, Pennington L, Weiss M, Xue Q, Yang B, Zhong W. (Amgen Inc.) Preparation of 2-hydroxy-1,3-diaminoalkanes including spiro substituted chroman derivatives as β-secretase modulators and their use for treatment Alzheimer's disease and related condition. PCT Int Appl 2007; WO2007062007.
158. Zhong W, Hitchcock S, Albrecht BK, Bartberger M, Brown J, Brown R, Chaffee SC, Cheng Y, Croghan M, Graceffa R, Harried S, Hickman D, Horne D, Hungate R, Judd T, Kaller M, Kreiman C, La D, Lopez P, Masse CE, Monenschein H, Nguyen T, Nixey T, Patel VF, Pennington L, Weiss M, Xue Q,Yang B. (Amgen Inc.) Preparation of 2-hydroxy-1,3-diaminoalkanes including spiro substituted chroman derivatives as β-secretase modulators and their use for treatment Alzheimer's disease and related condition. PCT Int Appl 2007; WO2007061670.
159. Faller A, Milner PH, Waard JG. (Smithkline Beecham P.L.C.) Hydroxyethylene compounds with Asp-2 inhibitory activity. PCT Int Appl 2003; WO2003045903.
160. Faller A, MacPherson DT, Milner PH, Stanway SJ, Trow LS. (Smithkline Beecham P.L.C.) Preparation of benzamide derivatives as inhibitors of Asp-2. PCT Int Appl 2003; WO2003045913.
161. Demont EH, Faller A, MacPherson DT, Milner PH, Naylor AR, Redshaw S, Stanway SJ,Vesey DR, Walter DR. (Glaxo Group Ltd) Preparation of hydroxyethylamine derivatives for the treatment of Alzheimer's disease. PCT Int Appl 2004; WO2004050619.
162. Redshaw S, Demont EH, Walter DS. (Glaxo Group Ltd) Preparation of tricyclic indole hydroxyethylamine derivatives and their use in the treatment of Alzheimer's disease. PCT Int Appl 2005; WO2005058615.
163. Demont EH, Redshaw S, Walter DS. (Glaxo Group Ltd) Preparation of 3-(1,1-dioxotetrahydro-1, 2-thiazin-2-yl) or 3-(1,1-dioxoisothiazolidin-2-yl) benzamido compounds for treatment of Alzheimer's disease. PCT Int Appl 2004; WO2004111022.
164. Demont EH, Redshaw S, Walter DS. (Glaxo Group Ltd) Preparation of hydroxyethylamine derivatives for the treatment of Alzheimer's disease. PCT Int Appl 2004; WO2004080376.
165. Demont EH, Redshaw S, Walter DS. (Glaxo Group Ltd) Preparation of hydroxydiaminopropyl tricyclic indolecarboxamides for treatment of β-amiloid related disease. PCT Int Appl 2004; WO2004094430.
166. Demont EH, Redshaw S,Walter DS. (Glaxo Group Ltd) Preparation of N,N′-substituted-1,3-diamino-2-oxopropane derivatives as Asp2 inhibitors for use against diseases characterized by elevated β-amyloid deposits, particularly Alzheimer's disease. PCT Int Appl 2005; WO2005113525.
167. Demont EH, Redshaw S, Walter DS. (Glaxo Group Ltd) Tricyclic indole derivatives for use in the treatment of Alzheimer's disease. PCT Int Appl 2006; WO2006040148.
168. Demont EH, Redshaw S, Walter DS. (Glaxo Group Ltd) Heterocyclic ketone compounds for treating Alzheimer's disease. PCT Int Appl 2006; WO2006040149.
169. Demont EH, Redshaw S, Walter DS. (Glaxo Group Ltd) Novel hydroxyethylamine and ketone compounds having Asp2 inhibitory activity. PCT Int Appl 2006; WO2006103088.
170. Decicco CP, Tebben AJ, Thompson LA, Combs AP. (Bristol-Myers Squibb Co.) Preparation of novel α-amino-γ-lactams as β-secretase inhibitors. PCT Int Appl 2004; WO2004013098.
171. Olson RE, Maduskuie TP, Thompson LA. (Bristol-Myers Squibb Co.) Preparation of (succinylamino)azepinones as inhibitors of Aβ protein. US Pat Appl 2004; US6794381.
172. Olson RE. (Bristol-Myers Squibb Co.) Preparation of succinoylaminobenzodiazepines as inhibitors of Aβ protein production for treating neurological disorders. US Pat Appl 2006; US7053084.
173. Thompson ILA, Boy KM,Shi JM, Macor JE. (Bristol-Myers Squibb Co.) Preparation of isophthalates as β-secretase inhibitors . PCT Int Appl 2006; WO2006099352.
174. Thompson LA, Shi J, Zusi FC, Dee MF, Macor JE. (Bristol-Myers Squibb Co.) Preparation of indoleacetic acid acyl guanidines as β-secretase (BACE) inhibitors. US Pat Appl 2007; US2007049589.
175. Gerritz S, Zhai W, Shi S, Zhu S, Good AC, Thompson LA III. (Bristol-Myers Squibb Co.) Preparation of isoxazolylcarbonyl- and isothiazolyl- carbonylguanidines as β-secretase (BACE). PCT Int Appl 2007; WO2007002214.
176. Malamas MS, Erdei JJ, Gunawan IS, Barnes KD, Johnson MR, Hui Y. (Wyeth, John & Br.) Diphenylimidazopyrimidine and imidazole amine as inhibitors of β-secretase. US Pat Appl 2005; US20050282826.
177. Malamas MS, Erdei JJ, Nawan IS, Npwak P, Harrison BL. (Wyeth, John & Br.) Amino-imidazolones for the inhibition of β-secretase. PCT Int Appl 2006; WO2006076284.
178. Malamas MS, Erdei JJ, Gunawan IS, Zhou P, Yan Y, Quagliato DA. (Wyeth, John & Br.) Amino 5,5-diphenylimidazolone derivatives for the inhibition of β-secretase. PCT Int Appl 2006; WO2006009653.
179. Malamas MS, Fobare WF, Solvibile WR, Lovering FE, Condon JS, Robichaud AJ. (Wyeth, John & Br.) Amino-pyridines as inhibitors of β-secretase. PCT Int Appl 2006; WO2006083760.
180. Cole DC, Manas ES, Stock JR, Condon JS, Jennings LD, Aulabaugh A, Chopra R, Cowling R, Ellingboe JW, Fan KY, Harrison BL, Hu Y, Jacobsen S, Jin G, Lin L, Lovering FE, Malamas MS, Stahl ML, Strand J, Sukhdeo MN, Svenson K, Turner MJ, Wagner E, Wu J, Zhou P, Bard J. Acylguanidines as small-molecule β-Secretase inhibitors. J Med Chem 2006;49:6158-6161. (Pubitemid 44595192)
181. Cole DC, Manas ES, Jennigs LD, Lovering FE, Stock JR, Moore WJ, Ellingboe JW, Condon JS, Sukhdeo MN, Zhou P, Wu J, Morris KM. (Wyeth, John & Br.) Preparation of azolylacylguanidines as β-secretase inhibitors. PCT Int Appl 2006; WO2006088711.
182. Fobare WF, Solvibile WR. (Wyeth, John & Br.) Substituted thienyl and furyl acylguanidines as β-secretase modulators. PCT Int Appl 2006; WO2006088694.
183. Baihua HU. (Wyeth, John & Br.) Terphenyl acylguanidines as β-secretase modulators. PCT Int Appl 2006; WO2006088705.
184. Albert JS, Andrisk D, Arnold J, Brown D, Callaghan O, Campbell J, Carr RAE, Chessari G, Congreve MS, Edwards P, Empfield JR, Frederickson M, Koether GM, Krumrine J, Mauger R, Murray CW, Patel S, Sylvester M, Throner S. (AstraZeneca AB and Astex Ther.) Preparation of substituted 2-aminopyrimidin- 4-ones for treating or preventing Aβ-related pathologies. PCT Int Appl 2006; WO2006041404 and 2006; WO2006041405.
185. Albert J, Edwards P, Empfield J. (AstraZeneca AB and Astex Ther.) Preparation of substituted 2-aminopyrimidin-4-ones for treating or preventing Aβ-related pathologies. PCT Int Appl 2007; WO2007058582.
186. Albert J, Andisik D, Edwards P, Sylvester M. (AstraZeneca AB and Astex Ther.) Preparation of substituted 2-aminopyrimidin-4-ones for treating or preventing Aβ-related pathologies. PCT Int Appl 2007; WO2007058580.
187. Albert J, Chessari G, Edwards P. (AstraZeneca AB and Astex Ther.) Preparation of substituted 2- aminopyrimidines for treating or preventing Aβ-related pathologies. PCT Int Appl 2007; WO2007058581.
188. Albert J, Arnold J, Chessari G, Congreve MS, Edwards P, Murrai C, Patel S. (AstraZeneca AB and Astex Ther.) Preparation of 2-aminoimidazole-4-ones for treatment of cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. PCT Int Appl 2007; WO2007058601.
189. Berg S, Burrows J, Chessari G, Congreve MS, Hedstroem J, Hellberg S, Hoegdin K, Kihlstroem J, Kolmodin K, Lindstroem J, Murray C, Patel S. (AstraZeneca AB) New 2-amino-3,5-dihydro-4Himidazol- 4-one derivatives and their use as BACE inhibitors for treatment cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. PCT Int Appl 2007; WO2007058602.
190. Albert J, Chessari G, Congreve MS, Edwards P, Murray C, Patel S, Sylvester M. (AstraZeneca AB and Astex Ther.) Preparation of dihydroisoquinolin-1-amines for treating or preventing Aβ-related pathologies, such as cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. PCT Int Appl 2007; WO2007058583.
191. Baxter E, Boyd R, Coats S, Jordan A, Reitz A, Reynolds CH, Scott M, Schulz M, DeWinter HLJ. (Janssen Pharm.) Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders. PCT Int Appl 2006; WO2006017844.
192. Baxter E, Bischoff FP, Braeken M, Coats S, Huang Y, Jordan A, Luo C, Mercken MH, Reynolds CH, Ross TM, Tounge BA, Schulz M, De Winte HLJ, Pieters SMA, Reitz AB. (Janssen Pharm.) Novel 2 - aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders. PCT Int Appl 2006; WO2006017836.
193. Bishoff FP, Bracken M, Pieters SMA, Mercken MH, De Winter HLJ, Berthelot DJ-C. (Janssen Pharm.) Novel 2 -aminoquinazoline derivatives, their preparation and use as inhibitors of β-secretase for treating Alzheimer's disease and related disorders. PCT Int Appl 2006; WO2006024932.
194. Reitz AB, Luo C, Huang Y, Ross TM, Baxter EE, Tounge BA, Parker MH, Strobel ED, Reynolds CH. (Janssen Pharm.) Preparation of 2-amino-3,4- dihydropyrido[3,4-d]pyrimidines as inhibitors of β-secretase (BACE). PCT Int Appl 2007; WO2007050612.
195. Baxter EW, Conway KA, Kennis L, Bischoff F, Mercken MH, DeWinter HL, Reynolds CH, Tounge BA, Luo C, Scott MK, Huang Y, Braeken M, Pieters SMA, Berthelot DJC, Masure S, Bruinzeel WD, Jordan AD, Parker MH, Boyd RE, Qu J, Alexander RS, Brenneman DE, Reitz B. (Johnson & Johnson Pharm.) 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (β-Site APP cleaving enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem 2007;50:4261-4264. (Pubitemid 47378825)
196. Bueno Melendo AB, Chen S-H, Erickson JA, Gonzalez-Garcia MR, Guo D, Marcos Llorente A, McCarthy JR, Shepherd TA, Sheehan SM, Yip YYM. (Eli Lilly & Co.) Preparation of amides as BACE inhibitors for treating Alzheimer's. PCT Int Appl 2005; WO2005108391.
197. Dally RD, Shepherd TAB, David M, Rojo Garcia MI. (Eli Lilly & Co.) Preparation of acylated 2-amino-1-(pyrrolidin-2-yl)ethanols and derivatives as BACE inhibitors for treating Alzheimer's. PCT Int Appl 2005; WO2005108358.
198. Durham TB, Hahn PJ, Kohn TJ, McCarthy JR, Broughton HB, Dally RD, Gonzalez-Garcia MR, Henry KJ Jr, Shepherd TA, Erickson JA, Ana B. (Eli Lilly & Co.) Preparation of acylated 2-amino-1-(morpholin-3-yl)ethanols and derivatives as BACE inhibitors for treating Alzheimer's. PCT Int Appl 2006; WO2006034093.
199. Auberson Y, Betschart C, Flohr S, Glatthar R, Simic O, Tintelnot-Blomley M, Troxler TJ, Vangrevelinghe E, Veenstra SJ. (Novartis AG and Novartis Pharma) A preparation of dibenz[b,f]oxepincarboxamide derivatives, useful for the treatment of neurological and vascular disorders related to β-amyloid generation and aggregation. PCT Int Appl 2005; WO2005014517.
200. Auberson Y, Glatthar R, Salter R, Simic O, Tintelnot-Blomley M. (Novartis AG and Norvatis Pharma) Preparation of substituted spirocyclic lactams as inhibitors of proteinase BACE1. PCT Int Appl 2005; WO2005035535.
201. Auberson Y, Betschart C, Glatthar R, Laumen K, Machauer R, Tintelnot-Blomley M, Troxler TJ, Veenstra SJ. Novartis AG and Novartis Pharma) Preparation of macrocyclic lactams for treatment of neurological or vascular disorders related to β-amyloid generation and/or aggregation. PCT Int Appl 2005; WO2005049585.
202. Lerchner A, Machauer R, Simic O, Tintelnot-Blomley M. (Novartis AG and Novartis Pharma) Preparation of macrocyclic compounds as BACE inhibitors for treating vascular and neurological disorders related to β-amyloid generation. PCT Int Appl 2006; WO2006074940.
203. Betschart C, Koller M, Laumen K, Lerchner A, Machauer R, McCarthy C, Tintelnot-Blomley M, Veenstra SJ. (Novartis AG and Novartis Pharma) Macrocyclic compounds useful as BACE inhibitors. PCT Int Appl 2007; WO2007077004.
204. Murray CW, Callaghan O, Chessari C, Cleasby A, Congreve M, Frederickson M, Hartshorn MJ, McMenamin R, Patel S, Wallis N. Application of fragment screening by X-ray crystallography to β-secretase. J Med Chem 2007;50:1116-1123. (Pubitemid 46496312)
205. Congreve M, Aharony D, Albert A, Callaghan O, Campbell J, Carr RAE, Chessari G, Cowan S, Edwards PD, Frederickson M, McMenamin R, Murray CW, Patel S, Wallis N. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase. J Med Chem 2007;50:1124-1132. (Pubitemid 46496313)
206. Yang W, Lu W, Lu Y, Zhong M, Sun J, Thomas AE, Wilkinson JM, Fucini RV, Lam M, Randal M, Shi X-P, Jacobs JW, McDowell RS, Gordon EM, Ballinger MD. (Sunesis Pharm. Inc.) Aminoethylenes: A tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. J Med Chem 2006;49:839-842.